文献速递临床试验与 GCP流行病学与生物统计

益生菌降低急性非缺氧性脑损伤成人呼吸机相关性肺炎:PROACT双盲多中心国际随机临床试验研究方案

Probiotics to reduce ventilator-associated pneumonia in adults with acute non‑anoxic brain injury: Study Protocol for a Double-Blind Multicenter Randomized International Clinical Trial (PROACT).
PubMed 文献 · Trials · 2025-11-10

PROACT研究为前瞻性、随机、双盲、安慰剂对照、多中心试验,计划纳入208例急性脑损伤后需有创机械通气的成人重症患者,1:1随机接受安慰剂(葡萄糖聚合物)或含嗜酸乳杆菌LA-5、植物乳杆菌、乳双歧杆菌BB12和布拉氏酵母菌的益生菌制剂,每日两次经鼻胃管及口咽部给药,主要终点为意向性治疗人群按现行国际指南定义的呼吸机相关性肺炎发生率。

要点

  • 急性脑损伤需有创机械通气的成人重症患者中,评估益生菌预防呼吸机相关性肺炎的疗效。
  • 主要终点为意向性治疗人群的呼吸机相关性肺炎发生率,按现行国际指南定义。
  • 样本量208例,把握度80%(α=0.05),效应量估计基于PROVAP研究。

核心结论

  • 该试验有望产生高质量证据,支持将益生菌纳入标准呼吸机相关性肺炎预防方案。
  • 研究结果可能对感染控制和微生物组靶向干预相关的临床实践指南与公共卫生政策有重要意义。

研究设计与样本

  • PROACT研究为前瞻性、随机、双盲、安慰剂对照、多中心试验,评估急性脑损伤后需有创机械通气的成人重症患者中益生菌预防的疗效。
  • 纳入急性脑损伤(如头部创伤、缺血性或出血性卒中)后需有创机械通气的成人重症患者,排除入组时疑似肺误吸或已存在肺部感染者以减少混杂。
  • 参与者按1:1随机接受安慰剂(葡萄糖聚合物)或含嗜酸乳杆菌LA-5、植物乳杆菌、乳双歧杆菌BB12和布拉氏酵母菌的益生菌制剂。
  • 干预每日两次经鼻胃管及口咽部给药,最长30天或至重症监护室出院。
  • 研究把握度80%(α=0.05),基于PROVAP研究的效应量估计,需总样本量208例。

关键数值与推荐

  • 主要终点为意向性治疗人群按现行国际指南定义的呼吸机相关性肺炎发生率。
  • 次要终点包括改良意向性治疗人群的呼吸机相关性肺炎发生率、导管相关血流感染、脓毒症和脓毒性休克发生、30天全因死亡率、重症监护室住院时长及机械通气时长。
  • 所有参与中心将标准呼吸机相关性肺炎预防集束化措施作为常规护理实施。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ventilator-associated pneumonia (VAP) remains a significant complication among critically ill patients, with associated mortality approaching 50%. Despite the implementation of established preventive strategies, additional interventions are urgently needed to further reduce the incidence of VAP. Probiotic therapy has emerged as a promising adjunctive approach; the benefits of probiotic therapy may be more pronounced in critically ill patients without pre-existing infections. The PROACT study will evaluate the prophylactic role of probiotics in a critically ill population with acute brain injury to reduce the VAP incidence, while also exploring microbiological endpoints and mortality to refine patient selection criteria. METHODS: The PROACT study is a prospective, randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the efficacy of probiotic prophylaxis in adult critically ill patients requiring invasive mechanical ventilation following acute brain injury (e.g., head trauma, ischemic or hemorrhagic stroke). Patients with suspected pulmonary aspiration or pre-existing pulmonary infections at enrollment are excluded to reduce confounding. Participants are randomized in a 1:1 ratio to receive either a placebo (glucose polymer) or a probiotic formulation containing Lactobacillus acidophilus LA-5, Lactobacillus plantarum, Bifidobacterium lactis BB12, and Saccharomyces boulardii. The assigned intervention is administered twice daily via nasogastric tube and oropharyngeal application for up to 30 days or until intensive care unit (ICU) discharge. The primary endpoint is the incidence of VAP, as defined by current international guidelines, in the intention-to-treat (ITT) population. Secondary endpoints include the incidence of VAP in the modified intention-to-treat (mITT) population, catheter-related bloodstream infections, occurrence of sepsis and septic shock, 30-day all-cause mortality, ICU length of stay, and duration of mechanical ventilation. The study is powered at 80% (α = 0.05) to detect a clinically meaningful difference based on effect size estimates based on the PROVAP study, requiring a total sample size of 208 patients. All participating centers implement standard VAP prevention bundles as part of routine care. DISCUSSION: By evaluating the efficacy of probiotic therapy in preventing VAP and the impact on mortality among critically ill brain-injured patients, this trial has the potential to generate high-quality evidence supporting the incorporation of probiotics into standard VAP prevention protocols. The findings may have significant implications for clinical practice guidelines and public health policy related to infection control and microbiome-targeted interventions in the intensive care setting. TRIAL REGISTRATION: Registered at ClinicalTrials.gov (identifier: [NCT06092554]). Registered on 2023-10-15.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Corriero A, Soloperto R, Giglio M, et al. Probiotics to reduce ventilator-associated pneumonia in adults with acute non‑anoxic brain injury: Study Protocol for a Double-Blind Multicenter Randomized International Clinical Trial (PROACT). Trials. 2025. PMID: 41214813. doi:10.1186/s13063-025-09230-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。